Pan-specific and partially selective dye-labeled peptidic inhibitors of the polycomb paralog proteins.


Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
01 01 2020
Historique:
received: 25 06 2019
revised: 09 10 2019
accepted: 17 10 2019
pubmed: 23 11 2019
medline: 28 1 2021
entrez: 23 11 2019
Statut: ppublish

Résumé

Epigenetic regulation of gene expression is in part controlled by post-translational modifications on histone proteins. Histone methylation is a key epigenetic mark that controls gene transcription and repression. There are five human polycomb paralog proteins (Cbx2/4/6/7/8) that use their chromodomains to recognize trimethylated lysine 27 on histone 3 (H3K27me3). Recognition of the methyllysine side chain is achieved through multiple cation-pi interactions within an 'aromatic cage' motif. Despite high structural similarity within the chromodomains of this protein family, they each have unique functional roles and are linked to different cancers. Selective inhibition of different CBX proteins is desirable for both fundamental studies and potential therapeutic applications. We report here on a series of peptidic inhibitors that target certain polycomb paralogs. We have identified peptidic scaffolds with sub-micromolar potency, and will report examples that are pan-specific and that are partially selective for individual members within the family. These results highlight important structure-activity relationships that allow for differential binding to be achieved through interactions outside of the methyllysine-binding aromatic cage motif.

Identifiants

pubmed: 31753799
pii: S0968-0896(19)31056-9
doi: 10.1016/j.bmc.2019.115176
pii:
doi:

Substances chimiques

Peptides 0
Polycomb-Group Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115176

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Natalia Milosevich (N)

Department of Chemistry, University of Victoria, Victoria, BC V8W 3V6, Canada.

James McFarlane (J)

Department of Chemistry, University of Victoria, Victoria, BC V8W 3V6, Canada.

Michael C Gignac (MC)

Department of Chemistry, University of Victoria, Victoria, BC V8W 3V6, Canada.

Janessa Li (J)

Department of Chemistry, University of Victoria, Victoria, BC V8W 3V6, Canada.

Tyler M Brown (TM)

Department of Chemistry, University of Victoria, Victoria, BC V8W 3V6, Canada.

Chelsea R Wilson (CR)

Department of Chemistry, University of Victoria, Victoria, BC V8W 3V6, Canada.

Lindsey Devorkin (L)

BC Cancer - Trev and Joyce Deeley Research Centre, Victoria, BC V8R 6V5, Canada.

Caitlin S Croft (CS)

Department of Chemistry, University of Victoria, Victoria, BC V8W 3V6, Canada.

Rebecca Hof (R)

Department of Chemistry, University of Victoria, Victoria, BC V8W 3V6, Canada.

Irina Paci (I)

Department of Chemistry, University of Victoria, Victoria, BC V8W 3V6, Canada.

Julian J Lum (JJ)

BC Cancer - Trev and Joyce Deeley Research Centre, Victoria, BC V8R 6V5, Canada.

Fraser Hof (F)

Department of Chemistry, University of Victoria, Victoria, BC V8W 3V6, Canada. Electronic address: fhof@uvic.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH